Healthcare Actuator Market Size And Share

• In January 2023, Abbott received FDA approval for the Navitor TAVI system to treat patients with severe aortic stenosis and those who are ineligible for open-heart surgery. Navitor has been newly introduced in the company's extensive transcatheter structural heart portfolio; it offers physicians and patients less invasive treatment alternatives for a range of serious heart conditions.
• In September 2020, Boston Scientific introduced the ACURATE neo2 aortic valve system in Europe. The next-generation TAVI technology—a new platform designed with multiple features to improve the clinical performance of the original ACURATE neo platform—had an extended indication for patients with aortic stenosis compared to the aortic valve system of the previous generation.